PubRank

Stefan Fröhling

Author PubWeight™ 117.95‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005 17.41
2 Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008 13.02
3 Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009 11.46
4 Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004 9.81
5 Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008 6.80
6 Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009 6.55
7 Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005 4.60
8 Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol 2006 4.49
9 TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 2011 3.32
10 High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood 2008 3.30
11 Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol 2011 3.13
12 AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell 2011 2.77
13 Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med 2010 2.50
14 K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors. Blood 2008 2.10
15 Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 2002 1.91
16 FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell 2007 1.74
17 The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. J Clin Invest 2007 1.61
18 Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol 2008 1.53
19 An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. Blood 2008 1.51
20 The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. Haematologica 2005 1.47
21 JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood 2006 1.41
22 Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica 2008 1.40
23 Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood 2007 1.28
24 Cdx4 dysregulates Hox gene expression and generates acute myeloid leukemia alone and in cooperation with Meis1a in a murine model. Proc Natl Acad Sci U S A 2006 1.19
25 CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling. J Clin Invest 2012 1.11
26 STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci U S A 2012 1.06
27 Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. J Clin Oncol 2013 1.03
28 Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol 2010 1.03
29 Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. Blood 2006 1.01
30 Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol 2010 0.98
31 Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. Blood 2008 0.98
32 Mutation analysis of the transcription factor PU.1 in younger adults (16 to 60 years) with acute myeloid leukemia: a study of the AML Study Group Ulm (AMLSG ULM). Blood 2003 0.96
33 Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. J Exp Med 2012 0.96
34 BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. J Clin Invest 2014 0.94
35 Array-based cytogenetic approaches in acute myeloid leukemia: clinical impact and biological insights. Semin Oncol 2012 0.88
36 Cdx4 is dispensable for murine adult hematopoietic stem cells but promotes MLL-AF9-mediated leukemogenesis. Haematologica 2010 0.81
37 Development of a real-time RT-PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia. Genes Chromosomes Cancer 2003 0.80
38 STK33 kinase is not essential in KRAS-dependent cells--letter. Cancer Res 2011 0.78
39 Deregulation of the CDX2-KLF4 axis in acute myeloid leukemia and colon cancer. Oncotarget 2013 0.77
40 Widespread over-expression of the non-clustered homeobox gene HLX in acute myeloid leukemia. Haematologica 2012 0.75
41 Ligand-induced MET signaling as targetable codependence in acute myeloid leukemia. Haematologica 2012 0.75